Jetstar to Charge for Overhead Cabin Bags From February 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
-- Company presentation scheduled for March 27, 2018 --
SOUTH SAN FRANCISCO, Calif., March 14, 2018 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will present at Needham & Company’s 17th Annual Healthcare Conference taking place March 27 to 28, 2018 in New York. Achaogen management will present at 2:00 p.m. Eastern Time on Tuesday, March 27th, 2018.
A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com. A replay of the presentation will be archived on the website for 30 days following the conference.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. The Company's second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination for the treatment of serious bacterial infections due to ESBL-producing Enterobacteriaceae. Achaogen's plazomicin program has been funded, and its C-Scape program is funded, in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections and additional disease areas. All product candidates, including plazomicin, are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Source: Achaogen, Inc. (NASDAQ:AKAO)
Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
[email protected]
Media Contact:
Denise T. Powell
Red House Consulting, LLC
[email protected]
